Related Experiment Video
Updated: Aug 16, 2026

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
[Regulation of hepatobiliary transporters in cholestatic liver disease]
Andreas Geier1, Carsten Gartung, Siegfried Matern
1Medizinische Klinik III, Universitätsklinikum der RWTH Aachen, Aachen, Germany. ageier@uk.aachen.de
Abstract:
Bile formation essentially depends on hepatobiliary organic anion transporters, which are exclusively localized either to the sinusoidal or canalicular membrane. Cloning of their genes has elucidated the pathophysiology of both hereditary and acquired forms of cholestasis. The regulation of these transporter genes occurs either by ubiquitous nuclear hormone receptors, which are activated by ligands including xenobiotics and bile acids, or by hepatocyte-specific trans-activators. Proinflammatory cytokines such as tumor necrosis factor alpha and interleukin-1beta represent additional mediators. Understanding of these regulatory pathways represents a mandatory prerequisite for any future therapeutic intervention in acute or chronic liver diseases.
More Related Videos
04:38Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Hepatic Drug Excretion: Influencing Factors
Hepatic Drug Clearance: Role of Transporters
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test